Overexpression of CXCL16 promotes a vulnerable plaque phenotype in Apolipoprotein E-Knockout Mice

Cytokine

Volumn 53, Issue 3, 2011, Pages 320-326

  Yi, Gui wen ^a   Zeng, Qiu tang ^a   Mao, Xiao bo ^a   Cheng, Min ^a   Yang, Xiao fang ^a   Liu, Hong tao ^a   Mao, Yi ^a   Guo, Min ^a   Ji, Qin wei ^a   Zhong, Yu cheng ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Atherosclerosis; CXCL16; Lentivirus; Vulnerable plaque

Indexed keywords

APOLIPOPROTEIN E; CXCL16 CHEMOKINE; LENTIVIRUS VECTOR; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROTIC PLAQUE; CAROTID ATHEROSCLEROSIS; CHOLESTEROL DIET; CONTROLLED STUDY; GENE INACTIVATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRANSGENE;

ANIMALS; APOLIPOPROTEINS E; BRACES; CAROTID ARTERIES; CHEMOKINE CCL2; CHEMOKINE CXCL6; CHOLESTEROL, DIETARY; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; MALE; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENOTYPE; PLAQUE, ATHEROSCLEROTIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

LENTIVIRUS; MUS;

EID: 79251606506     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.11.016     Document Type: Article

References (31)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
2. Charo I.F., Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006, 354:610-621.
3. Smith C., Halvorsen B., Otterdal K., Waehre T., Yndestad A., Fevang B., et al. High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: down-regulatory effects of statins. Cardiovasc Res 2008, 79:195-203.
4. Wuttge D.M., Zhou X., Sheikine Y., Wagsater D., Stemme V., Hedin U., et al. CXCL16/SR-PSOX is an interferon-γ-regulated chemokine and scavenger receptor expressed in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2004, 24:750-755.
5. Matloubian M., David A., Engel S., Ryan J.E., Cyster J.G. A transmembrane CXC chemokine is a ligand for HIV co-receptor Bonzo. Nat Immunol 2000, 1:298-304.
6. Shimaoka T., Kume N., Minami M., Hayashida K., Kataoka H., Kita T., et al. Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. J Biol Chem 2000, 275:40663-40666.
7. Tabata S., Kadowaki N., Kitawaki T., Shimaoka T., Yonehara S., Yoshie O., et al. Distribution and kinetics of SR-PSOX/CXCL16 and CXCR6 expression on human dendritic cell subsets and CD4+ T cells. J Leukoc Biol 2005, 77:777-786.
8. Wilbanks A., Zondlo S.C., Murphy K., Mak S., Soler D., Langdon P., et al. Expression cloning of the STRL33/BONZO/TYMSTR ligand reveals elements of CC, CXC, and CX3C chemokines. J Immunol 2001, 166:5145-5154.
9. Abel S., Hundhausen C., Mentlein R., Schulte A., Berkhout T.A., Broadway N., et al. The transmembrane CXC chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol 2004, 172:6362-6372.
10. Hofnagel O., Luechtenborg B., Plenz G., Robenek H. Expression of the novel scavenger receptor SR-PSOX in cultured aortic smooth muscle cells and umbilical endothelial cells. Arterioscler Thromb Vasc Biol 2002, 22:710-711.
11. Wagsater D., Olofsson P.S., Norgren L., Stenberg B., Sirsjo A. The chemokine and scavenger receptor CXCL16/SR-PSOX is expressed in human vascular smooth muscle cells and is induced by interferongamma. Biochem Biophys Res Commun 2004, 325:1187-1193.
12. Shashkin P., Simpson D., Mishin V., Chesnutt B., Ley K. Expression of CXCL16 in human T cells. Arterioscler Thromb Vasc Biol 2003, 23:148-149.
13. Kim C.H., Kunkel E.J., Boisvert J., Johnston B., Campbell J.J., Genovese M. C, et al. Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential. J Clin Invest 2001, 107:595-601.
14. Kim C.H., Johnston B., Butcher E.C. Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among Vα24+Vβ11+ NKT cell subsets with distinct cytokine-producing capacity. Blood 2002, 100:11-16.
15. Aslanian A.M., Charo I.F. Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis. Circulation 2006, 114:583-590.
16. Sheikine Y., Bang C.S., Nilsson L., Samnegard A., Hamsten A., Jonasson L., et al. Decreased plasma CXCL16/SR-PSOX concentration is associated with coronary artery disease. Atherosclerosis 2006, 188:462-466.
17. Gui-wen Y., Qiu-tang Z. Circulating CXCL16 is related to the severity of coronary artery stenosis. Arch Med Res 2008, 39:531-535.
18. Lehrke M., Millington S.C., Lefterova M., Cumaranatunge R.G., Szapary P., Wilensky R., et al. CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans. J Am Coll Cardiol 2007, 49:442-449.
19. Muller J.E., Tofler G.H., Stone P.H. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989, 79:733-743.
20. Faisal S., Ross T.M. Coronary artery disease current status of vulnerable plaque detection. Catheter Cardiovasc Interv 2009, 75:135-144.
21. Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis: characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 1983, 50:127-134.
22. Virmani R., Kolodgie F.D., Burke A.P., Farb A., Schwartz S.M. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000, 20:1262-1275.
23. Shah P.K. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 2003, 41:15S-22S.
24. Galis Z.S., Sukhova G.K., Lark M.W., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994, 94:2493-2503.
25. Iwai M., Chen R., Li Z., Shiuchi T., Suzuki J., Ide A., et al. Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice. Circulation 2005, 112:1636-1643.
26. von der Thusen J.H., van Berkel T.J., Biessen E.A. Induction of rapid atherogenesis by perivascular carotid collar placement in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Circulation 2001, 103:1164-1170.
27. Wolfgang K., Natalie K. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 2007, 27:15-26.
28. Jansson A.M., Aukrust P., Ueland Th., Smith C., Omland T., Hartford M., et al. Soluble CXCL16 predicts long-term mortality in acute coronary syndromes. Circulation 2009, 119:3181-3188.
29. Galkina E., Harry B.L., Ludwig A., Liehn E.A., Sanders J.M., Bruce A., et al. CXCR6 promotes atherosclerosis by supporting T-cell homing, interferon-gamma production, and macrophage accumulation in the aortic wall. Circulation 2007, 116:1801-1811.
30. Yuri S., Allan S. CXCL16/SR-PSOX-A friend or a foe in atherosclerosis?. Atherosclerosis 2008, 197:487-495.
31. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001, 104:365-372.